12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 1.221-5000 ng/ml |
Avelumab is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab targets the protein programmed death-ligand 1 (PD-L1).
Immobilized human PD-L1 at 0.5 μg/ml (50 μL/well) can bind to Avelumab with a linear range of 1.221 ng/ml-5 μg/ml.